Máté Kiss

Máté Kiss

Auto-generated profile, based on publicly available information

Máté Kiss

Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2023 in Science
Verified
Journal Article
Closed access
RBRuben Bill
Ruben Bill
PWPratyaksha Wirapati
Pratyaksha Wirapati
MMMarius Messemaker
Marius Messemaker
WRWhijae Roh
Whijae Roh
BZBeatrice Zitti
Beatrice Zitti
MPMikael J. Pittet
Mikael J. Pittet
Tumor microenvironments (TMEs) influence cancer progression but are complex and often differ between patients. Considering that microenvironment variations may reveal rules governing intratumoral cellular programs and disease outcome, we focused on tumor-to-tumor variation to examine 52 head and neck squamous cell carcinomas. We found that macrophage polarity—defined by CXCL9 and SPP1 (CS) expression but not by conventional M1 and M2 markers—had a noticeably strong prognostic association. CS macrophage polarity also identified a highly coordinated network of either pro- or antitumor variables, which involved each tumor-associated cell type and was spatially organized. We extended these findings to other cancer indications. Overall, these results suggest that, despite their complexity, TMEs coordinate coherent responses that control human cancers and for which CS macrophage polarity is a relevant yet simple variable.

23 December 2016 in Nature Communications
Verified
Journal Article
Open access
DLDamya Laoui
Damya Laoui
JKJiri Keirsse
Jiri Keirsse
YMYannick Morias
Yannick Morias
EOEva Van Overmeire
Eva Van Overmeire
XGXenia Geeraerts
Xenia Geeraerts
JGJo A. Van Ginderachter
Jo A. Van Ginderachter
Various steady state and inflamed tissues have been shown to contain a heterogeneous DC population consisting of developmentally distinct subsets, including cDC1s, cDC2s and monocyte-derived DCs, displaying differential functional specializations. The identification of functionally distinct tumour-associated DC (TADC) subpopulations could prove essential for the understanding of basic TADC biology and for envisaging targeted immunotherapies. We demonstrate that multiple mouse tumours as well as human tumours harbour ontogenically discrete TADC subsets. Monocyte-derived TADCs are prominent in tumour antigen uptake, but lack strong T-cell stimulatory capacity due to NO-mediated immunosuppression. Pre-cDC-derived TADCs have lymph node migratory potential, whereby cDC1s efficiently activate CD8+ T cells and cDC2s induce Th17 cells. Mice vaccinated with cDC2s displayed a reduced tumour growth accompanied by a reprogramming of pro-tumoural TAMs and a reduction of MDSCs, while cDC1 vaccination strongly induces anti-tumour CTLs. Our data might prove important for therapeutic interventions targeted at specific TADC subsets or their precursors.

1 January 2018 in Immunity
Verified
Journal Article
Open access
ZCZsolt Czimmerer
Zsolt Czimmerer
BDBence Daniel
Bence Daniel
Attila HorvathAttila Horvath
Attila Horvath
DRDominik Rückerl
Dominik Rückerl
GNGergely Nagy
Gergely Nagy
LNLaszlo Nagy
Laszlo Nagy
The molecular basis of signal-dependent transcriptional activation has been extensively studied in macrophage polarization, but our understanding remains limited regarding the molecular determinants of repression. Here we show that IL-4-activated STAT6 transcription factor is required for the direct transcriptional repression of a large number of genes during in vitro and in vivo alternative macrophage polarization. Repression results in decreased lineage-determining transcription factor, p300, and RNA polymerase II binding followed by reduced enhancer RNA expression, H3K27 acetylation, and chromatin accessibility. The repressor function of STAT6 is HDAC3 dependent on a subset of IL-4-repressed genes. In addition, STAT6-repressed enhancers show extensive overlap with the NF-κB p65 cistrome and exhibit decreased responsiveness to lipopolysaccharide after IL-4 stimulus on a subset of genes. As a consequence, macrophages exhibit diminished inflammasome activation, decreased IL-1β production, and pyroptosis. Thus, the IL-4-STAT6 signaling pathway establishes an alternative polarization-specific epigenenomic signature resulting in dampened macrophage responsiveness to inflammatory stimuli.

1 August 2013 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MKMate Kiss
Mate Kiss
ZCZsolt Czimmerer
Zsolt Czimmerer
LNLaszlo Nagy
Laszlo Nagy

1 August 2018 in Cellular Immunology
Verified
Journal Article
Closed access
MKMate Kiss
Mate Kiss
SGSofie Van Gassen
Sofie Van Gassen
KMKiavash Movahedi
Kiavash Movahedi
YSYvan Saeys
Yvan Saeys
DLDamya Laoui
Damya Laoui

17 September 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MKMáté Kiss
Máté Kiss
ACAarushi Audhut Caro
Aarushi Audhut Caro
GRGeert Raes
Geert Raes
DLDamya Laoui
Damya Laoui
Monocytes influence multiple aspects of tumor progression, including antitumor immunity, angiogenesis, and metastasis, primarily by infiltrating tumors, and differentiating into tumor-associated macrophages. Emerging evidence suggests that the tumor-induced systemic environment influences the development and phenotype of monocytes before their arrival to the tumor site. As a result, circulating monocytes show functional alterations in cancer, such as the acquisition of immunosuppressive activity and reduced responsiveness to inflammatory stimuli. In this review, we summarize available evidence about cancer-induced changes in monopoiesis and its impact on the abundance and function of monocytes in the periphery. In addition, we describe the phenotypical alterations observed in tumor-educated peripheral blood monocytes and highlight crucial gaps in our knowledge about additional cellular functions that may be affected based on transcriptomic studies. We also highlight emerging therapeutic strategies that aim to reverse cancer-induced changes in monopoiesis and peripheral monocytes to inhibit tumor progression and improve therapy responses. Overall, we suggest that an in-depth understanding of systemic monocyte reprogramming will have implications for cancer immunotherapy and the development of clinical biomarkers.